225 Ac-DOTA-LM3 PRRT for Neuroendocrine Tumors | Saarland University Hospital

The nuclear medicine unit at Saarland University Hospital (UKS), under the expert leadership of renowned specialists like Prof. Dr. Samer Ezziddin, proudly offers a pioneering therapeutic approach for advanced neuroendocrine neoplasms. The 225Ac-DOTA-LM3 peptide receptor radionuclide therapy (PRRT) represents the absolute forefront of theranostic medicine. This highly specialized targeted alpha therapy is designed to deliver localized, highly lethal radiation directly to tumor cells, offering a vital lifeline for patients facing complex oncological challenges. As one of the premier institutions globally to successfully translate this specific antagonist-based alpha therapy into clinical practice, Saarland University Hospital provides a meticulously personalized treatment pathway grounded in cutting-edge radiological science. This advanced therapeutic intervention is distinctly indicated for patients diagnosed with metastatic neuroendocrine tumors (NETs) that exhibit high somatostatin receptor (SSTR) expression. It serves as a critical, next-generation option for individuals who have developed resistance to standard beta-emitter therapies, such as 177Lu-DOTATATE or 177Lu-DOTATOC, or for those presenting with aggressive disease, such as high hepatic tumor burdens and highly glucometabolic lesions. When conventional PRRT and systemic chemotherapies no longer halt disease progression, 225Ac-DOTA-LM3 serves as a powerful salvage therapy, capable of overcoming acquired radioresistance. The unparalleled efficacy of this treatment is driven by its dual-innovation mechanism, which marries the destructive physics of Actinium-225 (225Ac) with the superior molecular targeting of the DOTA-LM3 peptide. Unlike traditional radiopharmaceuticals that act as receptor agonists, LM3 is a somatostatin receptor subtype 2 (SSTR2) antagonist. This vital structural distinction enables the molecule to bind to a vastly broader array of receptor binding sites on the tumor cell surface, resulting in massive tumor uptake and significantly prolonged retention of the radioactive payload. Once securely attached to the cancer cell, the Actinium-225 isotope releases highly energetic alpha particles. These particles deliver a massive dose of radiation over a remarkably short microscopic range, inducing clustered, irreparable double-strand DNA breaks within the tumor while actively sparing surrounding healthy organs and tissues. Patients at our Homburg facility benefit from a highly tailored, multidisciplinary clinical protocol. Following comprehensive molecular imaging and dosimetric evaluation using advanced PET/CT diagnostics, our nuclear medicine experts design a bespoke treatment schedule. Depending on the individual's prior exposure to radiation and specific tumor biology, the therapy is administered either as a potent monotherapy or through a sophisticated TANDEM approach, strategically co-administering Actinium-225 alongside Lutetium-177. The radiopharmaceutical itself is synthesized on-site in our state-of-the-art radiopharmacy, guaranteeing the highest possible standards of radiochemical purity and stability. Treatment is carried out during a comfortable, closely monitored inpatient stay, during which our clinical staff proactively manage and assess hematological, renal, and hepatic profiles to ensure exceptional safety and patient tolerability. The ultimate objective of the 225Ac-DOTA-LM3 PRRT program at Saarland University Hospital is to achieve durable disease control while profoundly restoring the patient's overall well-being. Documented clinical milestones at our facility have shown remarkable intraindividual success, demonstrating partial remissions, the stabilization of previously unchecked disease, and dramatic reductions in tumor-related pain and fatigue. By effectively shrinking therapy-resistant lesions and mitigating debilitating systemic symptoms, this advanced alpha-PRRT consistently helps patients regain their energy and quality of life, cementing its reputation as a global leader in transformative oncological care.